Den kliniske farmakoligiske undersøgelse WP18551 viste følgende: efter administration af en enklet intravenøs dosis på 6 mg (15 minutters infusion) steg middel AUC0- 24 med henholdsvis 14% og 86% hos patienter med lettere (middel estimeret CLcr=68, 1 ml/ min) og moderat (middel estimeret CLcr=41, 2 ml/ min) nedsat nyrefunktion, sammenlignet med raske frivillige (middel estimeret CLcr=120 ml/ min).
In clinical pharmacology trial WP18551, after a single dose intravenous administration of 6 mg (15 minutes infusion), mean AUC0-24 increased by 14% and 86%, respectively, in subjects with mild (mean estimated CLcr=68.1 mL/ min) and moderate (mean estimated CLcr=41.2 mL/ min) renal impairment compared to healthy volunteers (mean estimated CLcr=120 mL/ min).